


IPW

# TRANSMITTAL FORM



Application Serial Number	10/737,208
Filing Date	December 16, 2003
First Named Inventor	Gillies
Group Art Unit	1653
Examiner Name	Not yet assigned
Attorney Docket No.	LEX-023
Patent No.	Not applicable
Issue Date	Not applicable


## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Check Attached <input type="checkbox"/> Copy of Fee Transmittal Form  <input type="checkbox"/> Amendment/Response <input type="checkbox"/> Preliminary <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____]  <input type="checkbox"/> Petition for Extension of Time  <input checked="" type="checkbox"/> Information Disclosure Statement <input checked="" type="checkbox"/> Form PTO-1449 <input checked="" type="checkbox"/> Copies of cited references (B1-B107 and C1-C261) <input type="checkbox"/> Check Attached  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Sequence Listing submission <input type="checkbox"/> Paper Copy/CD <input type="checkbox"/> Computer Readable Copy <input type="checkbox"/> Statement verifying identity of above	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application  <input type="checkbox"/> Formal Drawing(s)  <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal  <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers)  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application  <input type="checkbox"/> Small Entity Statement  <input type="checkbox"/> CD(s) for large table or computer program  <input type="checkbox"/> Amendment After Allowance  <input type="checkbox"/> Request for Certificate of Correction <input type="checkbox"/> Certificate of Correction (in duplicate)	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences  <input type="checkbox"/> Appeal Brief (in triplicate)  <input type="checkbox"/> Status Inquiry  <input checked="" type="checkbox"/> Return Receipt Postcard  <input type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8  <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8  <input type="checkbox"/> Additional Enclosure(s) (please identify below)
--	---	--

## CORRESPONDENCE ADDRESS

Direct all correspondence to: Patent Administrator  
 Testa, Hurwitz & Thibault, LLP  
 High Street Tower  
 125 High Street  
 Boston, MA 02110  
 Tel. No.: (617) 248-7000  
 Fax No.: (617) 248-7100

## SIGNATURE BLOCK

Respectfully submitted,  
  
 Date: August 13, 2004  
 Reg. No. 48,645  
 Tel. No.: (617) 248-7697  
 Fax No.: (617) 248-7100  
 Brian A. Fairchild, Ph.D.  
 Attorney for the Applicants  
 Testa, Hurwitz & Thibault, LLP  
 High Street Tower  
 125 High Street  
 Boston, MA 02110



PATENT  
Attorney Docket No. LEX-023

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Gillies *et al.* CONF. NO.: 6855  
SERIAL NO.: 10/737,208 GROUP NO.: 1653  
FILING DATE: December 16, 2003 EXAMINER: Not yet assigned  
TITLE: IMMUNOCYTOKINE SEQUENCES AND USES THEREOF

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. In accordance with the U.S. Patent and Trademark Office's partial waiver of the requirement under 37 C.F.R. § 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. § 1.97, this statement is being filed (CHECK ONE):

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. § 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. § 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. § 1.17(p), namely **\$180.00**, is included herein, or

- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. § 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application. Please charge any fee deficiency or credit any overpayment to deposit account 20-0531.

Respectfully submitted,




Brian A. Fairchild, Ph.D.  
Attorney for Applicants  
Testa, Hurwitz, & Thibault, LLP  
High Street Tower  
125 High Street  
Boston, Massachusetts 02110

August 13, 2004  
Reg. No. 48,645  
Tel. No.: (617) 248-7697  
Fax No.: (617) 248-7100

3090008

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT



ATTORNEY DOCKET NO. LEX-023

APPLICANT(S): Gillies *et al.*

SERIAL NO. 10/737,208

CONF. NO. 6855

FILING DATE: December 16, 2003 GROUP: 1653

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A1	07/348,237	5/5/89	Rosenblum et al.			
	A2	4,196,265	4/1/80	Koprowski et al.			
	A3	4,469,797	9/4/84	Albarella			
	A4	4,676,980	6/30/87	Segal et al.			
	A5	4,703,008	10/27/87	Lin			
	A6	4,816,567	3/28/89	Cabilly et al.			
	A7	4,946,778	8/7/90	Ladner et al.			
	A8	5,019,368	5/28/91	Epstein et al.			
	A9	5,073,627	12/17/91	Curtis et al.			
	A10	5,114,711	5/19/92	Bell et al.			
	A11	5,116,964	5/26/92	Capon et al.			
	A12	5,199,942	4/6/93	Gillis			
	A13	5,225,538	7/6/93	Capon et al.			
	A14	5,225,539	7/6/93	Winter			
	A15	5,258,498	11/2/93	Huston et al.			
	A16	5,314,995	5/24/94	Fell, Jr. et al.			
	A17	5,349,053	9/20/94	Landolfi			
	A18	5,359,035	10/25/94	Habermann			
	A19	5,441,868	8/15/95	Lin			
	A20	5,457,038	10/10/95	Trinchieri et al.			
	A21	5,514,582	5/7/96	Capon et al.			
	A22	5,538,866	7/23/96	Israeli et al.			
	A23	5,541,087	7/30/96	Lo et al.			
	A24	5,543,297	8/6/96	Cromlish, et al.			
	A25	5,547,933	8/20/96	Lin			
	A26	5,552,524	09/03/96	Basinski et al.			
	A27	5,585,089	12/17/96	Queen et al.			
EXAMINER				DATE CONSIDERED			

<b>FORM PTO - 1449</b>				<b>ATTORNEY DOCKET NO. LEX-023</b>			
<b>INFORMATION DISCLOSURE STATEMENT</b>				<b>APPLICANT(S): Gillies <i>et al.</i></b>			
				<b>SERIAL NO. 10/737,208</b>		<b>CONF. NO. 6855</b>	
				<b>FILING DATE: December 16, 2003</b>		<b>GROUP: 1653</b>	
<b>U.S. PATENT DOCUMENTS</b>							
<b>EXAM. INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE IF APPROPRIATE</b>
	A28	5,601,819	2/11/97	Wong et al.			
	A29	5,609,846	3/11/97	Goldenberg			
	A30	5,618,698	4/8/97	Lin			
	A31	5,624,821	4/29/97	Winter et al.			
	A32	5,639,725	6/17/97	O'Reilly et al.			
	A33	5,645,835	7/8/97	Fell, Jr. et al.			
	A34	5,650,150	7/22/97	Gillies			
	A35	5,650,492	7/22/97	Gately et al.			
	A36	5,667,776	9/16/97	Zimmerman et al.			
	A37	5,679,543	10/21/97	Lawlis			
	A38	5,688,679	11/18/97	Powell			
	A39	5,691,309	11/25/97	Basinski et al.			
	A40	5,709,859	1/20/98	Aruffo et al.			
	A41	5,719,266	02/17/98	DiMarchi et al.			
	A42	5,723,125	3/3/98	Chang et al.			
	A43	5,726,044	3/10/98	Lo et al.			
	A44	5,728,552	3/17/98	Fujisawa et al.			
	A45	5,733,876	3/31/98	O'Reilly et al.			
	A46	5,756,349	5/26/98	Lin			
	A47	5,756,461	05/26/98	Stephens			
	A48	5,759,551	6/2/98	Ladd et al.			
	A49	5,770,195	6/23/98	Hudziak et al.			
	A50	5,800,810	9/1/98	Doyle et al.			
	A51	5,807,715	9/15/98	Morrison et al.			
	A52	5,827,516	10/27/98	Urban et al.			
	A53	5,837,682	11/17/98	Folkman et al.			
	A54	5,843,423	12/1/98	Lyman et al.			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

<b>FORM PTO - 1449</b>				<b>ATTORNEY DOCKET NO. LEX-023</b>			
<b>INFORMATION DISCLOSURE STATEMENT</b>				<b>APPLICANT(S): Gillies <i>et al.</i></b>			
				<b>SERIAL NO. 10/737,208</b>		<b>CONF. NO. 6855</b>	
				<b>FILING DATE: December 16, 2003</b>		<b>GROUP: 1653</b>	
<b>U.S. PATENT DOCUMENTS</b>							
<b>EXAM. INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE IF APPROPRIATE</b>
	A55	5,854,205	12/29/98	O'Reilly et al.			
	A56	5,856,298	1/5/99	Strickland			
	A57	5,858,347	1/12/99	Bauer et al.			
	A58	5,885,795	3/23/99	O'Reilly et al.			
	A59	5,886,178	3/23/99	Allen et al.			
	A60	5,888,772	3/30/99	Okasinski et al.			
	A61	5,891,680	4/6/99	Lieschke et al.			
	A62	5,908,626	6/1/99	Chang et al.			
	A63	5,922,685	7/13/99	Rakhmievich et al.			
	A64	5,955,422	9/21/99	Lin			
	A65	5,994,104	11/30/99	Anderson et al.			
	A66	5,994,126	11/30/99	Steinman et al.			
	A67	6,080,409	6/27/00	Laus et al.			
	A68	6,086,875	7/11/00	Blumberg et al.			
	A69	6,100,387	8/8/00	Herrmann et al.			
	A70	6,169,070	1/2/01	Chen et al.			
	A71	6,171,588	1/9/01	Carron et al.			
	A72	6,231,536	5/15/01	Lentz			
	A73	6,277,375	8/21/01	Ward			
	A74	6,284,536	9/4/01	Morrison et al.			
	A75	6,335,176	1/1/02	Inglese et al.			
	A76	6,340,742	1/22/02	Burg et al.			
	A77	6,348,192	2/19/02	Chan et al.			
	A78	6,406,689	6/18/02	Falkenberg et al.			
	A79	6,429,199	8/6/02	Krieg et al.			
	A80	6,444,792	9/3/02	Gray et al.			
	A81	6,475,717	11/5/02	Enssle et al.			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			

FORM PTO - 1449

## INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO. LEX-023

APPLICANT(S): Gillies *et al.*

SERIAL NO. 10/737,208

CONF. NO. 6855

FILING DATE: December 16, 2003 GROUP: 1653

## U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	A82	6,485,726	11/26/02	Blumberg et al.			
	A83	6,500,641	12/31/02	Chen et al.			
	A84	6,506,405	1/14/03	Desai et al.			
	A85	6,551,592	4/22/03	Lindhofer et al.			
	A86	6,583,272	6/24/03	Bailon			
	A87	6,586,398	7/1/03	Kinstler et al.			
	A88	6,617,135	9/9/03	Gillies et al.			
	A89	6,646,113	11/11/03	Dreyfuss et al.			
	A90	2001/0053539	12/20/01	Lauffer et al.			
	A91	2002/0037558	3/28/02	Lo et al.			
	A92	2002/0081664	6/27/02	Lo et al.			
	A93	2002/0142374	10/3/02	Gallo et al.			
	A94	2002/0146388	10/10/02	Gillies			
	A95	2002/0147311	10/10/02	Gillies et al.			
	A96	2002/0192222	12/19/02	Blumberg et al.			
	A97	2002/0193570	12/19/02	Gillies et al.			
	A98	2003/0003529	1/2/03	Bayer			
	A99	2003/0044423	3/6/03	Gillies et al.			
	A100	2003/0049227	3/13/03	Gillies et al.			
	A101	2003/0105294	6/5/03	Gillies et al.			
	A102	2003/0012789	1/6/03	Blumberg et al.			
	A103	2003/0139365	7/24/03	Lo et al.			
	A104	2003/0139575	7/24/03	Gillies			
	A105	2003/0157054	8/21/03	Gillies et al.			
	A106	2003/0166163	9/4/03	Gillies			
	A107	2003/0166877	9/4/03	Gillies et al.			
	A108	2004/0013640	1/22/04	Zardi et al.			
EXAMINER				DATE CONSIDERED			

<b>FORM PTO - 1449</b>				<b>ATTORNEY DOCKET NO. LEX-023</b>			
<b>INFORMATION DISCLOSURE STATEMENT</b>				<b>APPLICANT(S): Gillies <i>et al.</i></b>			
				<b>SERIAL NO. 10/737,208</b>		<b>CONF. NO. 6855</b>	
				<b>FILING DATE: December 16, 2003    GROUP: 1653</b>			
<b>U.S. PATENT DOCUMENTS</b>							
<b>EXAM. INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE IF APPROPRIATE</b>
	A109	2004/0033210	2/19/04	Gillies			
	A110	2004/0043457	3/4/04	Schumacher et al.			
	A111	2004/0053366	3/18/04	Lo et al.			
	A112	2004/0072299	4/15/04	Gillies et al.			
	A113	2004/0082039	4/29/04	Gillies et al.			
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>			



<b>FORM PTO – 1449</b>				ATTORNEY DOCKET NO. LEX-023					
<b>INFORMATION DISCLOSURE STATEMENT</b>				APPLICANT(S): Gillies <i>et al.</i>					
				SERIAL NO. 10/737,208		CONF. NO. 6855			
				FILING DATE: December 16, 2003 GROUP: 1653					
<b>FOREIGN PATENT DOCUMENTS</b>									
EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B1	0 158 198 A1	10/16/85	EP					Y
	B2	0 211 769 A2	2/25/87	EP					Y
	B3	0 256 714 A2	2/24/88	EP					Y
	B4	0 294 703 A2	12/14/88	EP					Y
	B5	0 308 936 B1	3/29/89	EP					Y
	B6	0 314 317 B1	5/3/89	EP					Y
	B7	0 318 554 B1	6/7/89	EP					Y
	B8	0 319 012 A2	6/7/89	EP					Y
	B9	0 326 120 B1	8/2/89	EP					Y
	B10	0 350 230 A2	1/10/90	EP					Y
	B11	0 375 562 B1	6/27/90	EP					Y
	B12	0 396 387 A2	11/7/90	EP					Y
	B13	0 439 095 A2	7/31/91	EP					Y
	B14	0 511 747 A1	11/4/92	EP					Y
	B15	0 601 043 B1	6/15/94	EP					Y
	B16	0 640 619 A1	3/1/95	EP					Y
	B17	0 668 353 A1	8/23/95	EP					Y
	B18	0 706 799 A2	4/17/96	EP					Y
	B19	0 790 309 A1	8/20/97	EP					Y
	B20	1 088 888 A1	4/4/01	EP					Y
	B21	21725/88	3/23/89	AU					Y
	B22	93100115.3	7/14/93	CN					N
	B23	93100115.3	7/14/93	CN				Y	Y
	B24	37 12985 A1	11/2/88	DE					N
	B25	37 12985	11/2/88	DE				Y	Y
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

<b>FORM PTO – 1449</b>					<b>ATTORNEY DOCKET NO. LEX-023</b>				
<b>INFORMATION DISCLOSURE STATEMENT</b>					APPLICANT(S): Gillies <i>et al.</i>				
					SERIAL NO. 10/737,208      CONF. NO. 6855				
					FILING DATE: December 16, 2003      GROUP: 1653				
<b>FOREIGN PATENT DOCUMENTS</b>									
EXAM INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	B26	2 292 382 A	2/21/96	GB					Y
	B27	63-267278	11/4/88	JP					N
	B28	63-267278	11/4/88	JP				Y	Y
	B29	63-267296	11/4/88	JP					N
	B30	63-267296	11/4/88	JP				Y	Y
	B31	0 237 019 A2	9/16/87	EP				English counterpart of JP 63- 267296	Y
	B32	WO 86/01533	3/13/86	PCT					Y
	B33	WO 88/00052	1/14/88	PCT					Y
	B34	WO 88/09344	12/1/88	PCT					Y
	B35	WO 89/02922	4/6/89	PCT					Y
	B36	WO 89/09620	10/19/89	PCT				Abstract in English	N
	B37	WO 90/03801	4/19/90	PCT					Y
	B38	WO 91/00360	1/10/91	PCT					Y
	B39	WO 91/04329	04/04/91	PCT					Y
	B40	WO 91/08298	6/13/91	PCT					Y
	B41	WO 91/13166	9/5/91	PCT					Y
	B42	WO 91/14438	10/3/91	PCT					Y
	B43	WO 92/02240	2/20/92	PCT					Y
	B44	WO 92/08495	5/29/92	PCT					Y
	B45	WO 92/08801	5/29/92	PCT					Y
	B46	WO 92/16562	10/1/92	PCT					Y
	B47	WO 93/03157	2/18/93	PCT					Y
	B48	WO 93/10229	5/27/93	PCT					Y
	B49	WO 93/20185	10/14/93	PCT					
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

<b>FORM PTO – 1449</b>					<b>ATTORNEY DOCKET NO. LEX-023</b>				
<b>INFORMATION DISCLOSURE STATEMENT</b>					<b>APPLICANT(S): Gillies <i>et al.</i></b>				
					<b>SERIAL NO. 10/737,208      CONF. NO. 6855</b>				
					<b>FILING DATE: December 16, 2003      GROUP: 1653</b>				
<b>FOREIGN PATENT DOCUMENTS</b>									
<b>EXAM INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY CODE</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE</b>	<b>ABSTRACT ONLY</b>	<b>ENGLISH LANG (Y/N)</b>
	B50	WO 94/24160	10/27/94	PCT					Y
	B51	WO 94/25055	11/10/94	PCT					Y
	B52	WO 95/05468	2/23/95	PCT					Y
	B53	WO 95/21258	8/10/95	PCT					Y
	B54	WO 95/28427	10/26/95	PCT					Y
	B55	WO 95/31483	11/23/95	PCT					Y
	B56	WO 96/04388	02/15/96	PCT					Y
	B57	WO 96/05309	2/22/96	PCT					Y
	B58	WO 96/08570	3/21/96	PCT					Y
	B59	WO 96/18412	6/20/96	PCT					Y
	B60	WO 96/31526	10/10/96	PCT					Y
	B61	WO 97/00317	1/3/97	PCT					Y
	B62	WO 97/00319	1/3/97	PCT					Y
	B63	WO 97/15666	5/1/97	PCT					Y
	B64	WO 97/20062	6/5/97	PCT					Y
	B65	WO 97/24137	7/10/97	PCT					Y
	B66	WO 97/24440	7/10/97	PCT					Y
	B67	WO 97/26335	7/24/97	PCT					Y
	B68	WO 97/30089	8/21/97	PCT					Y
	B69	WO 97/33617	9/18/97	PCT					Y
	B70	WO 97/33619	9/18/97	PCT					Y
	B71	WO 97/34631	9/25/97	PCT					Y
	B72	WO 97/43316	11/20/97	PCT					Y
	B73	WO 98/00127	1/8/98	PCT					Y
	B74	WO 98/06752	2/19/98	PCT					Y
	B75	WO 98/28427	7/2/98	PCT					Y
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

<b>FORM PTO – 1449</b>					<b>ATTORNEY DOCKET NO. LEX-023</b>				
<b>INFORMATION DISCLOSURE STATEMENT</b>					<b>APPLICANT(S): Gillies <i>et al.</i></b>				
					<b>SERIAL NO. 10/737,208      CONF. NO. 6855</b>				
					<b>FILING DATE: December 16, 2003      GROUP: 1653</b>				
<b>FOREIGN PATENT DOCUMENTS</b>									
<b>EXAM INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY CODE</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE</b>	<b>ABSTRACT ONLY</b>	<b>ENGLISH LANG (Y/N)</b>
	B76	WO 98/30706	7/16/98	PCT					Y
	B77	WO 98/46257	10/22/98	PCT					Y
	B78	WO 98/59244	12/30/98	PCT					Y
	B79	WO 99/02709	01/21/99	PCT					Y
	B80	WO 99/03887	01/28/99	PCT					Y
	B81	WO 99/29732	6/17/99	PCT					Y
	B82	WO 99/43713	9/2/99	PCT					Y
	B83	WO 99/52562	10/21/99	PCT					Y
	B84	WO 99/53958	10/28/99	PCT					Y
	B85	WO 99/60128	11/25/99	PCT					Y
	B86	WO 99/62944	12/09/99	PCT					Y
	B87	WO 99/66054	12/23/99	PCT					Y
	B88	WO 00/11033	3/2/00	PCT					Y
	B89	WO 00/24893	5/4/00	PCT					
	B90	WO 00/34317	06/15/00	PCT					Y
	B91	WO 00/40615	7/13/00	PCT					Y
	B92	WO 00/68376	11/16/00	PCT					Y
	B93	WO 00/69913	11/23/00	PCT					Y
	B94	WO 00/78334	12/28/00	PCT					Y
	B95	WO 01/07081	2/1/01	PCT					Y
	B96	WO 01/10912	2/15/01	PCT					Y
	B97	WO 01/36489	5/25/01	PCT					Y
	B98	WO 01/58957	8/16/01	PCT					
	B99	WO 02/02143	1/10/02	PCT					
	B100	WO 02/066514	8/29/02	PCT					Y
	B101	WO 02/072605	9/19/02	PCT					
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

<b>FORM PTO – 1449</b>					<b>ATTORNEY DOCKET NO. LEX-023</b>				
<b>INFORMATION DISCLOSURE STATEMENT</b>					<b>APPLICANT(S): Gillies <i>et al.</i></b>				
					<b>SERIAL NO. 10/737,208      CONF. NO. 6855</b>				
					<b>FILING DATE: December 16, 2003    GROUP: 1653</b>				
<b>FOREIGN PATENT DOCUMENTS</b>									
<b>EXAM INIT.</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY CODE</b>	<b>CLASS</b>	<b>SUB CLASS</b>	<b>FILING DATE</b>	<b>ABSTRACT ONLY</b>	<b>ENGLISH LANG (Y/N)</b>
	B102	WO 02/079232	10/10/02	PCT					
	B103	WO 02/079415	10/10/02	PCT					
	B104	WO 02/090566	11/14/02	PCT					
	B105	WO 03/015697	2/27/03	PCT					Y
	B106	WO 03/048334	6/12/03	PCT					
	B107	WO 03/077834	9/25/03	PCT					Y
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>				

<b>FORM PTO – 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTORNEY DOCKET NO. LEX-023  APPLICANT(S): Gillies <i>et al.</i>  SERIAL NO. 10/737,208                      CONF. NO. 6855  FILING DATE: December 16, 2006    GROUP: 1653	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C1	Abaza et al., (1992), "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin," <u>Journal of Protein Chemistry</u> , 11(5):433-444.	
	C2	Abstract XP-002116766, Lupulescu, (1996), "Prostaglandins, Their Inhibitors and Cancer," <u>Prostaglandins, Leukotrienes and Essential Fatty Acids</u> , 54(2):83-94.	
	C3	Afonso et al., (1994), "The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major," <u>Science</u> , 263:235-237.	
	C4	Angal et al., (1993), "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody," <u>Molecular Immunology</u> , 30(1):105-108.	
	C5	Arenberg et al., (1996), "Interferon- $\gamma$ -inducible Protein 10 (IP-10) is an Angiostatic Factor that Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," <u>J. Exp. Med.</u> , 184:981-992.	
	C6	Bacha et al., (1988), "Interleukin 2 Receptor-Targeted Cytotoxicity: Interleukin 2 Receptor-mediated Action of a Diphtheria Toxin-related Interleukin 2 Fusion Protein," <u>J. Exp. Med.</u> , 167:612-622.	
	C7	Bachelot et al., (1998), "Retrovirus-Mediated Gene Transfer of an Angiostatin-Endostatin Fusion Protein with Enhanced Anti-Tumor Properties In Vivo," <u>Proceedings of the Annual Meeting of the American Association for Cancer Research</u> , 39:271, Abstract #1856 (XP-002089298).	
	C8	Barnett et al., (1994), "Purification, Characterization and Selective Inhibition of Human Prostaglandin G/H Synthase 1 and 2 Expressed in the Baculovirus System," <u>Biochimica et Biophysica Acta</u> , 1209:130-139.	
	C9	Baselga et al., (1998), "Recombinant Humanized Anti-HER2 Antibody (Herceptin <sup>TM</sup> ) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER3/ <i>neu</i> Overexpressing Human Breast Cancer Xenografts," <u>Cancer Research</u> , 58:2825-2831.	
	C10	Batova et al., (1999), "The Ch14.18-GM-CSF Fusion Protein Is Effective at Mediating Antibody-dependent Cellular Cytotoxicity and Complement-dependent Cytotoxicity in Vitro," <u>Clinical Cancer Research</u> , 5:4259-4263.	
	C11	Batra et al., (1993), "Insertion of Constant Region Domains of Human IgG1 into CD4-PE40 Increases Its Plasma Half-Life," <u>Molecular Immunology</u> , 30(4):379-386.	
	C12	Becker et al., (1996), "An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response," <u>Proc. Natl. Acad. Sci. USA</u> , 93:7826-7831.	
	C13	Becker et al., (1996), "Eradication of Human Hepatic and Pulmonary Melanoma Metastases in SCID Mice by Antibody-interleukin 2 Fusion Proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 93:2702-2707.	
	C14	Becker et al., (1996), "Long-lived and Transferable Tumor Immunity in Mice after Targeted Interleukin-2 Therapy," <u>J. Clin. Invest.</u> , 98(12):2801-2804.	
	C15	Becker et al., (1996), "T Cell-mediated Eradication of Murine Metastatic Melanoma Induced by Targeted Interleukin-2 Therapy," <u>J. Exp. Med.</u> , 183(50):2361-2366.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C16	Beutler et al., (1988), "Tumor Necrosis, Cachexia, Shock, and Inflammation: A Common Mediator," <u>Annual Rev. Biochem.</u> , 57:505-518.	
	C17	Bissery et al., (1997), "The Taxoids," in <u>Cancer Therapeutics: Experimental and Clinical Agents</u> , Teicher (ed.), pp. 175-193.	
	C18	Bitonti et al., (2002), "Transepithelial Absorption of an Erythropoietin-Fc Fusion Protein After Delivery to the Central Airways," <u>Respiratory Drug Delivery</u> , 8:309-312.	
	C19	Bjorn et al., (1985), "Evaluation of Monoclonal Antibodies for the Development of Breast Cancer Immunotoxins," <u>Cancer Research</u> , 45:1214-1221.	
	C20	Boehm et al., (1997), "Antiangiogenic Therapy of Experimental Cancer Does Not Induce Acquired Drug Resistance," <u>Nature</u> , 390:404-407.	
	C21	Boehm et al., (1998), "Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity," <u>Biochemical and Biophysical Research Communications</u> , 252:190-194.	
	C22	Boissel et al., (1993), "Erythropoietin Structure-Function Relationships: Mutant Proteins that Test a Model of Tertiary Structure," <u>The Journal of Biological Chemistry</u> , 268(21):15983-15993.	
	C23	Briggs et al., (1974), "Hepatic Clearance of Intact and Desialylated Erythropoietin," <u>American Journal of Physiology</u> , 227(6):1385-1388.	
	C24	Brooks et al., (1994), "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <u>Cell</u> , 79:1157-1164.	
	C25	Buchli et al., (1993), "Structural and Biologic Properties of a Human Aspartic Acid-126 Interleukin-2 Analog," <u>Archives of Biochemistry and Biophysics</u> , 307(2):411-415.	
	C26	Burgess et al., (1990), "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>Journal of Cell Biology</u> , 111:2129-2138.	
	C27	Canfield et al., (1991), "The Binding Affinity of Human IgG for its High Affinity Fc Receptor is Determined by Multiple Amino Acids in the CH2 Domain and Is Modulated by the Hinge Region," <u>J. Exp. Med.</u> , 173(6):1483-1491.	
	C28	Cao et al., (1996), "Kringle Domains of Human Angiostatin: Characterization of the Anti-Proliferative Activity of Endothelial Cells," <u>The Journal of Biological Chemistry</u> , 271(46):29461-29467.	
	C29	Cao et al., (1997), "Kringle 5 of Plasminogen is a Novel Inhibitor of Endothelial Cell Growth," <u>The Journal of Biological Chemistry</u> , 272(36):22924-22928.	
	C30	Capon et al., (1989), "Designing CD4 Immunoadhesins for AIDS Therapy," <u>Nature</u> , 337:525-531.	
	C31	Caton et al., (1986), "Structural and Functional Implications of a Restricted Antibody Response to a Defined Antigenic Region on the Influenza Virus Hemagglutinin," <u>The EMBO Journal</u> , 5(7):1577-1587.	
	C32	Chan et al., (1991), "Induction of Interferon $\gamma$ Production by Natural Killer Cell Stimulatory Factor: Characterization of the Responder Cells and Synergy with Other Inducers," <u>J. Exp. Med.</u> , 173: 869-879.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C33	Chang et al., (1989), "Overview of Interleukin-2 as an Immunotherapeutic Agent," <u>Seminars in Surgical Oncology</u> , 5:385-390.	
	C34	Chang et al., (1996), "A Point Mutation in Interleukin-2 that Alters Ligand Internalization," <u>Journal of Biological Chemistry</u> , 271(23):13349-13355.	
	C35	Chapman et al., (1994), "Mapping Effector Functions of a Monoclonal Antibody to GD3 by Characterization of a Mouse-Human Chimeric Antibody," <u>Cancer Immuno. Immunother.</u> , 39:198-204.	
	C36	Chaudhary et al., (1988), "Selective Killing of HIV-infected Cells by Recombinant Human CD4- <i>Pseudomonas</i> Exotoxin Hybrid Protein," <u>Nature</u> , 335:370-372.	
	C37	Chaudhary et al., (1989), "A Recombinant Immunotoxin Consisting of Two Antibody Variable Domains Fused to <i>Pseudomonas</i> Exotoxin," <u>Nature</u> , 339:394-397.	
	C38	Chen et al., (1997), "Eradication of Murine Bladder Carcinoma by Intratumor Injection of a Bicistronic Adenoviral Vector Carrying cDNAs for the IL-12 Heterodimer and Its Inhibition by the IL-12 p40 Subunit Homodimer," <u>Journal of Immunology</u> , 159(1):351-358.	
	C39	Cheon et al., (1994), "High-affinity Binding Sites for Related Fibroblast Growth Factor Ligands Reside Within Different Receptor Immunoglobulin-like Domains," <u>Proc. Natl. Acad. Sci. USA</u> , 91: 989-993.	
	C40	Chuang et al., (1993), "Effect of New Investigational Drug Taxol on Oncolytic Activity and Stimulation of Human Lymphocytes," <u>Gynecologic Oncology</u> , 49:291-298.	
	C41	Chuang et al., (1994), "Alteration of Lymphocyte Microtubule Assembly, Cytotoxicity, and Activation by the Anticancer Drug Taxol," <u>Cancer Research</u> , 54:1286-1291.	
	C42	Cohen et al., (1996), "Human Leptin Characterization," <u>Nature</u> , 382:589.	
	C43	Cole et al., (1997), "Human IgG2 Variants of Chimeric Anti-CD3 Are Nonmitogenic to T Cells," <u>Journal of Immunology</u> , 159:3613-3621.	
	C44	Collins et al., (1988), "Identification of Specific Residues of Human Interleukin 2 That Affect Binding to the 70-kDa Subunit (p70) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 85:7709-7713.	
	C45	Colombo et al., (1996), "Amount of Interleukin 12 Available at the Tumor Site is Critical for Tumor Regression," <u>Cancer Research</u> , 56:2531-2534.	
	C46	Conner et al., (2004), "Ex vivo Evaluation of Anti-EpCAM Immunocytokine huKS-IL2 in Ovarian Cancer," <u>J. Immunotherapy</u> , 27:211-219.	
	C47	Cruse et al., (eds.), (1995), <u>Illustrated Dictionary of Immunology</u> , pp.156-158, CRC Press, NY.	
	C48	D'Amato et al., (1994), "Thalidomide is an Inhibitor of Angiogenesis," <u>Proc. Natl. Acad. Sci. USA</u> , 91:4082-4085.	
	C49	D'Andrea et al., (1992), "Production of Natural Killer Cell Stimulatory Factor (Interleukin 12) by Peripheral Blood Mononuclear Cells," <u>J. Exp. Med.</u> , 176:1387-1398.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C50	Darling et al., (2002), "Glycosylation of Erythropoietin Affects Receptor Binding Kinetics: Role of Electrostatic Interactions," <u>Biochemistry</u> , 41:14524-14531.	
	C51	Davis et al., (2003), "Immunocytokines: Amplification of Anti-cancer Immunity," <u>Cancer Immunol. Immunother.</u> , 52:297-308.	
	C52	de la Salle et al., (1996), "FcγR on Human Dendritic Cells," in <u>Human IgG Receptors</u> , pp. 39-55, van de Winkel et al. (eds.), R.G. Landes Co.	
	C53	Ding et al., (1988), "Zinc-Dependent Dimers Observed in Crystals of Human Endostatin," <u>Proc. Natl. Acad. Sci. USA</u> , 95:10443-10448.	
	C54	Dolman et al., (1998), "Suppression of Human Prostate Carcinoma Metastases in Severe Combined Immunodeficient Mice by Interleukin 2 Immunocytokine Therapy," <u>Clin. Cancer Research</u> , 4(10):2551-2557.	
	C55	Dorai et al., (1991), "Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function," <u>Hybridoma</u> , 10(2):211-217.	
	C56	Dorai et al., (1992), "Role of Inter-Heavy and Light Chain Disulfide Bonds in the Effector Functions of Human IgG1," <u>Molecular Immunology</u> , 29(12):1487-1491.	
	C57	Duncan et al., (1988), "The Binding Site for C1q on IgG," <u>Nature</u> , 332:738-740.	
	C58	Earnest et al., (1992), "Piroxicam and Other Cyclooxygenase Inhibitors: Potential for Cancer Chemoprevention," <u>J. Cell. Biochem., Supp.</u> , 161:156-166.	
	C59	Egrie et al., (2001), "Development and Characterization of Novel Erythropoiesis Stimulating Protein (NESP)," <u>Nephrol. Dial. Transplant.</u> , 16(Suppl 3):3-13.	
	C60	Eisenthal, (1990), "Indomethacin Up-regulates the Generation of Lymphokine-Activated Killer-cell Activity and Antibody-dependent Cellular Cytotoxicity Mediated by Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 31:342-348.	
	C61	Elliott et al., (1996), "Fine-Structure Epitope Mapping of Antierythropoietin Monoclonal Antibodies Reveals a Model of Recombinant Human Erythropoietin Structure," <u>Blood</u> , 87(7):2702-2713.	
	C62	Elliott et al., (1997), "Mapping of the Active Site of Recombinant Human Erythropoietin," <u>Blood</u> , 89(2):493-502.	
	C63	Fell et al., (1991), "Genetic Construction and Characterization of A Fusion Protein Consisting of a Chimeric F(ab') with Specificity for Carcinomas and Human IL-2," <u>J. Immunology</u> , 146(7):2446-2452.	
	C64	Fell et al., (1992), "Chimeric L6 Anti-tumor Antibody: Genomic Construction, Expression, and Characterization of the Antigen Binding Site," <u>J. Biological Chemistry</u> , 267:15552-15558.	
	C65	Fibi et al., (1995), "N- and O-Glycosylation Muteins of Recombinant Human Erythropoietin Secreted From BHK-21 Cells," <u>Blood</u> , 85(5):1229-1236.	
	C66	Friedman et al., (1998), "Leptin and the Regulation of Body Weight in Mammals," <u>Nature</u> , 395:763-770.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C67	Frost et al., (1997), "A Phase I/IB Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a Plus Interleukin-2 in Children with Refractory Neuroblastoma," <u>Cancer</u> , 80(2):317-333.	
	C68	Gan et al., (1999), "Specific Enzyme-linked Immunosorbent Assays for Quantitation of Antibody-cytokine Fusion Proteins," <u>Clinical and Diagnostic Laboratory Immunology</u> , 6(2):236-42.	
	C69	Gasson et al., (1984), "Purified Human Granulocyte Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <u>Science</u> , 226:1339-1342.	
	C70	Gately et al., (1998), "The Interleukin-12/Interleukin-12-Receptor System: Role in Normal and Pathologic Immune Responses," <u>Annu. Rev. Immunol.</u> , 16:495-521.	
	C71	Gillesen et al., (1995), "Mouse Interleukin-12 (IL-12) p40 Homodimer: A Potent IL-12 Antagonist," <u>Eur. J. Immunol.</u> , 25:200-206.	
	C72	Gillies et al., (1989), "Expression of Human Anti-Tetanus Toxoid Antibody in Transfected Murine Myeloma Cells," <u>Bio/Technology</u> , 7:799-804.	
	C73	Gillies et al., (1989), "High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes," <u>J. Immunol. Methods</u> , 125:191-202.	
	C74	Gillies et al., (1990), "Antigen Binding and Biological Activities of Engineered Mutant Chimeric Antibodies with Human Tumor Specificities," <u>Hum. Antibod. Hybridomas</u> , 1(1):47-54.	
	C75	Gillies et al., (1991), "Expression of Genetically Engineered Immunoconjugates of Lymphotoxin and a Chimeric Anti-ganglioside GD2 Antibody," <u>Hybridoma</u> , 10(3):347-56.	
	C76	Gillies et al., (1991), "Targeting Human Cytotoxic T Lymphocytes to Kill Heterologous Epidermal Growth Factor Receptor-Bearing Tumor Cells: Tumor-Infiltrating Lymphocyte/Hormone Receptor/Recombinant Antibody," <u>J. Immunology</u> , 146(3):1067-1071.	
	C77	Gillies et al., (1992), "Antibody-Targeted Interleukin 2 Stimulates T-Cell Killing of Autologous Tumor Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 89:1428-1432.	
	C78	Gillies et al., (1993), "Biological Activity and <i>In Vivo</i> Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4(3):230-235.	
	C79	Gillies et al., (1998), "Antibody-IL-12 Fusion Proteins are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases," <u>J. Immunology</u> , 160:6195-6203.	
	C80	Gillies et al., (1999), "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," <u>Cancer Research</u> , 59:2159-2166.	
	C81	Gillies et al., (2002), "Bi-functional Cytokine Fusion Proteins for Gene Therapy and Antibody-targeted Treatment of Cancer," <u>Cancer Immunol. Immunother.</u> , 51(8):449-60.	
	C82	Gillies et al., (2002), "Improved Circulating Half-life and Efficacy of an Antibody-interleukin 2 Immunocytokine Based on Reduced Intracellular Proteolysis," <u>Clin. Cancer Research</u> , 8(1):210-216.	
	C83	Gillis et al., (1978), "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <u>J. Immunology</u> , 120(6):2027-2032.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C84	Goeddel et al., (1986), "Tumor Necrosis Factors: Gene Structure and Biological Activities," <u>Cold Spring Harb. Symp. Quant. Biol.</u> , 51:597-609.	
	C85	Greene et al., (1975), "Neuronal Properties of Hybrid Neuroblastoma X Sympathetic Ganglion Cells," <u>Proc. Natl. Acad. Sci. USA</u> , 72(12):4923-4927.	
	C86	Gren et al., (1983), "A New Type of Leukocytic Interferon," English Translation of <u>Dokl. Akad. Nauk. SSSR.</u> , 269(4):986-990.	
	C87	Griffon-Etienne et al., (1999), "Taxane-induced Apoptosis Decompresses Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: Clinical Implications," <u>Cancer Research</u> , 59:3776-3782.	
	C88	Grimaldi et al., (1989), "The t(5;14) Chromosomal Translocation in a Case of Acute Lymphocytic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene," <u>Blood</u> , 73(8):2081-2085.	
	C89	Guyre et al., (1997), "Increased Potency of Fc-receptor-targeted Antigens," <u>Cancer Immunol. Immunother.</u> , 45:146-148.	
	C90	Hammerling et al., (1996), "In Vitro Bioassay for Human Erythropoietin Based on Proliferative Stimulation of an Erythroid Cell Line and Analysis of Carbohydrate-dependent Microheterogeneity," <u>Journal of Pharmaceutical and Biomedical Analysis</u> , 14:1455-1469.	
	C91	Handgretinger et al., (1995), "A Phase I Study of Human/Mouse Chimeric Anti-ganglioside GD2 Antibody ch14.18 in Patients with Neuroblastoma," <u>European J. Cancer</u> , 31A(2):261-267.	
	C92	Hank et al., (1996), "Activation of Human Effector Cells by a Tumor Reactive Recombinant Anti-ganglioside GD2 Interleukin-2 Fusion Protein (ch14.18-IL2)," <u>Clin Cancer Research</u> , 2(12):1951-1959.	
	C93	Hank et al., (2003), "Determination of Peak Serum Levels and Immune Response to the Humanized Anti-ganglioside Antibody-interleukin-2 Immunocytokine," in <u>Methods in Molecular Medicine</u> , Vol. 85: <u>Novel Anticancer Drug Protocols</u> , Buolamwini et al., (eds.), pp. 123-131, Humana Press Inc., Totowana, NJ.	
	C94	Haraguchi, (1994), "Isolation of GD3 Synthase Gene by Expression Cloning of GM3 $\alpha$ -2,8-sialyltransferase cDNA using anti-GD2 Monoclonal Antibody," <u>Proc. Natl. Acad. Sci. USA</u> , 91(22):10455-10459.	
	C95	Harris et al., (1993), "Therapeutic Antibodies - the Coming of Age," <u>Trends in Biotechnology</u> , 11:42-44.	
	C96	Harris, (1995), "Processing of C-terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <u>J. Chromatography A</u> , 705:129-134.	
	C97	Harvill et al., (1995), "An IgG3-IL2 Fusion Protein Activates Complement, Binds Fc $\gamma$ RI, Generates LAK Activity and Shows Enhanced Binding to the High Affinity IL-2R," <u>Immunotechnology</u> , 1:95-105.	
	C98	Harvill et al., (1996), "In Vivo Properties of an IgG3-IL-2 Fusion Protein: A General Strategy for Immune Potentiation," <u>J. Immunology</u> , 157(7):3165-3170.	
	C99	Hazama et al., (1993), "Adjuvant-Independent Enhanced Immune Responses to Recombinant Herpes Simplex Virus Type 1 Glycoprotein D by Fusion with Biologically Active Interleukin-2," <u>Vaccine</u> , 11(6):629-636.	
	C100	He et al., (1998), "Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for Both E- and P-Selectin," <u>J. Immunology</u> , 160:1029-1035.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C101	Heijnen et al., (1996), "Antigen Targeting to Myeloid-specific Human FcγRI/CD64 Triggers Enhanced Antibody Responses in Transgenic Mice," <u>J. Clin. Invest.</u> , 97(2):331-338.	
	C102	Heinzel et al., (1997), "In Vivo Production and Function of IL-12 p40 Homodimers," <u>J. Immunology</u> , 158:4381-4388.	
	C103	Hellstrom et al., (1986), "Antitumor Effects of L6, an IgG2a Antibody that Reacts with Most Human Carcinomas," <u>Proc. Natl. Acad. Sci. USA</u> , 83: 7059-7063.	
	C104	Henkart, (1985), "Mechanism of Lymphocyte-Mediated Cytotoxicity," <u>Ann. Rev. Immunol.</u> , 3:31-58.	
	C105	Herrmann et al., (1989), "Hematopoietic Responses With Advanced Malignancy Treated With Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," <u>Journal of Clinical Oncology</u> , 7(2):159-167.	
	C106	Hezareh et al., (2001), "Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1," <u>J. Virology</u> , 75(24):12161-12168.	
	C107	Hohenester et al., (1998), "Crystal Structure of the Angiogenesis Inhibitor Endostatin at 1.5 Å Resolution," <u>EMBO Journal</u> , 17(6):1656-1664.	
	C108	Holden et al., (2001), "Augmentation of Anti-Tumor Activity of KS-IL2 Immunocytokine with Chemotherapeutic Agents," <u>Proceedings of the American Association for Cancer Research</u> , 42:683, Abstract No. 3675 (XP-002195344).	
	C109	Holden et al., (2001), "Augmentation of Antitumor Activity of an Antibody-Interleukin 2 Immunocytokine with Chemotherapeutic Agents," <u>Clinical Cancer Research</u> , 7:2862-2869.	
	C110	Hoogenboom et al., (1991), "Construction and Expression of Antibody-tumor Necrosis Factor Fusion Proteins," <u>Molecular Immunology</u> , 28(9):1027-1037.	
	C111	Hoogenboom et al., (1991), "Targeting of Tumor Necrosis Factor to Tumor Cells Secretion by Myeloma Cells of a Genetically Engineered Antibody-Tumor Necrosis Factor Hybrid Molecule," <u>Biochim. and Biophys. Acta</u> , 1096(4):345-354 (Abstract).	
	C112	Hornick et al., (1999), "Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed Against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors," <u>Clin. Cancer Research</u> , 5:51-60.	
	C113	Hu et al., (1996), "A Chimeric Lym-1/Interleukin 2 Fusion Protein for Increasing Tumor Vascular Permeability and Enhancing Antibody Uptake," <u>Cancer Research</u> , 56:4998-5004.	
	C114	Huck et al., (1986), "Sequence of a Human Immunoglobulin Gamma 3 Heavy Chain Constant Region Gene: Comparison With the Other Human Cγ genes," <u>Nucleic Acids Research</u> , 14(4):1779-1789.	
	C115	Hurn et al., (1980), "Production of Reagent Antibodies," <u>Methods in Enzymology</u> , 70: 104-142.	
	C116	Huse et al., (1989), "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246:1275-1281.	
	C117	Idusogie et al., (2000), "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <u>J. Immunology</u> , 164(8):4178-4184.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

FORM PTO – 1449		ATTORNEY DOCKET NO. LEX-023	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>	
		SERIAL NO. 10/737,208	CONF. NO. 6855
		FILING DATE: December 16, 2006 GROUP: 1653	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C118	Imboden et al., (2001), "The Level of MHC Class I Expression on Murine Adenocarcinoma Can Change the Antitumor Effector Mechanism of Immunocytokine Therapy," <u>Cancer Research</u> , 61(4):1500-7.	
	C119	Ingber et al., (1990), "Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumour Growth," <u>Nature</u> , 348:555-557.	
	C120	Isenman et al., (1975), "The Structure and Function of Immunoglobulin Domains: II. The Importance of Interchain Disulfide Bonds and the Possible Role of Molecular Flexibility in the Interaction between Immunoglobulin G and Complement," <u>J. Immunology</u> , 114(6):1726-1729.	
	C121	Jones et al., (1986), "Replacing the Complementarity-determining Regions in a Human Antibody with Those from a Mouse," <u>Nature</u> , 321:522-525.	
	C122	Ju et al., (1987), "Structure-Function Analysis of Human Interleukin-2: Identification of Amino Acid Residues for Biological Activity," <u>Journal of Biological Chemistry</u> , 262(12):5723-5731.	
	C123	Jung et al., (1986), "Activation of Human Peripheral Blood Mononuclear Cells by Anti-T3: Killing of Tumor Target Cells Coated with Anti-target-anti-T3 Conjugates," <u>Proc. Natl. Acad. Sci. USA</u> , 83:4479-4483.	
	C124	Junghans et al., (1996), "The Protection Receptor of IgG Catabolism is the B2-microglobulin-containing Neonatal Intestinal Transport Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 93(11):5512-5516.	
	C125	Kang et al., (1991), "Antibody Redesign by Chain Shuffling from Random Combinatorial Immunoglobulin Libraries," <u>Proc. Natl. Acad. Sci. USA</u> , 88:11120-11123.	
	C126	Kappel et al., (1992), "Regulating Gene Expression in Transgenic Animals," <u>Current Opinion in Biotechnology</u> , 3:548-553	
	C127	Kato et al., (1997), "Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 283:520-527.	
	C128	Kato et al., (1998), "Pharmacokinetics of Erythropoietin in Genetically Anemic Mice," <u>Drug Metabolism and Disposition</u> , 26(2):126-131.	
	C129	Karpovsky et al., (1984), "Production of Target-Specific Effector Cells using Hetero-Cross Linked Aggregate Containing Anti-Target Cell and AntiFcγ Receptor Antibodies," <u>Journal of Experimental Medicine</u> , 160(6):1686-1701.	
	C130	Kendra et al., (1999), "Pharmacokinetics and Stability of the ch14.18-Interleukin-2 Fusion Protein in Mice," <u>Cancer Immunol. Immunother.</u> , 48:219-229.	
	C131	Kim et al., (1997), "An Ovalbumin-IL-12 Fusion Protein is More Effective than Ovalbumin Plus Free Recombinant IL-12 in Inducing a T Helper Cell Type 1-dominated Immune Response and Inhibiting Antigen-Specific IgE Production," <u>J. Immunology</u> , 158(9):4137-4144.	
	C132	Kim et al., (1999), "Cytokine Molecular Adjuvants Modulate Immune Responses Induced by DNA Vaccine Constructs for HIV-1 and SIV," <u>Journal of Interferon and Cytokine Research</u> , 19:77-84.	
	C133	Kitamura et al., (1989), "Establishment and Characterization of a Unique Human Cell Line that Proliferates Dependently on GM-CSF, IL-3, or Erythropoietin," <u>Journal of Cellular Physiology</u> , 140:323-334.	
EXAMINER		DATE CONSIDERED	

<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C134	Ko et al., (2004), "Safety, Pharmacokinetics, and Biological Pharmacodynamics of the Immunocytokine EMD 273066 (huKS-IL2)," <u>J. Immunotherapy</u> , 27:232-239.	
	C135	Kranz et al., (1984), "Attachment of an Anti-receptor Antibody to Non-target Cells Renders Them Susceptible to Lysis by a Clone of Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci. USA</u> , 81:7922-7926.	
	C136	Kuo et al., (2001), "Oligomerization-dependent Regulation of Motility and Morphogenesis by the Collagen XVIII NC1/Endostatin Domain," <u>Journal of Cell Biology</u> , 152(6):1233-1246.	
	C137	Kushner et al., (2001), "Phase II Trial of the Anti-GD2 Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma," <u>J. Clinical Oncology</u> , 19(22):4189-94.	
	C138	LaVallie et al., (1993), "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <u>Journal of Biological Chemistry</u> , 268(31):23311-23317.	
	C139	Lazar et al., (1988), "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Molecular and Cellular Biology</u> , 8(3):1247-1252.	
	C140	LeBerthon et al., (1991), "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <u>Cancer Research</u> , 51:2694-2698.	
	C141	Lieschke, et al., (1997), "Bioactive Murine and Human Interleukin-12 Fusion Proteins which Retain Antitumor Activity In Vivo," <u>Nature Biotechnology</u> , 15(1):35-40.	
	C142	Linsley et al., (1991), "CTLA-4 is a Second Receptor for B Cell Activation Antigen B7," <u>J. Exp. Med.</u> , 174(3):561-569.	
	C143	Liu et al., (1985), "Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8648-8652.	
	C144	Liu et al., (1988), "Hormone Conjugated with Antibody to CD3 Mediates Cytotoxic T Cell Lysis of Human Melanoma Cells," <u>Science</u> , 239:395-398.	
	C145	Liu et al., (1998), "Immunostimulatory CpG Oligodeoxynucleotides Enhance the Immune Response to Vaccine Strategies Involving Granulocyte-Macrophage Colony-Stimulating Factor," <u>Blood</u> , 92(10):3730-3736.	
	C146	Lo et al., (1992), "Expression and Secretion of an Assembled Tetrameric CH2-deleted Antibody in <i>E. Coli</i> ," <u>Hum. Antibod. Hybridomas</u> , 3:123-128.	
	C147	Lo et al., (1998), "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," <u>Protein Engineering</u> , 11(6):495-500.	
	C148	Locatelli et al., (2001), "Darbepoetin alfa Amgen," <u>Current Opinion in Investigational Drugs</u> , 2:1097-1104.	
	C149	Lode et al., (1997), "Targeted Interleukin-2 Therapy for Spontaneous Neuroblastoma Metastases to Bone Marrow," <u>J. Natl. Cancer Inst.</u> , 89(21):1586-94.	
	C150	Lode et al., (1998), "Immunocytokines: A Promising Approach to Cancer Immunotherapy," <u>Pharmacol. Ther.</u> , 80(3):277-292.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTORNEY DOCKET NO. LEX-023  APPLICANT(S): Gillies <i>et al.</i>  SERIAL NO. 10/737,208                      CONF. NO. 6855  FILING DATE: December 16, 2006    GROUP: 1653	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C151	Lode et al., (1998), "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," <u>Blood</u> , 91(5):1706-1715.	
	C152	Lode et al., (1999), "Synergy Between an Antiangiogenic Integrin $\alpha_v$ Antagonist and an Antibody-cytokine Fusion Protein Eradicates Spontaneous Tumor Metastases," <u>Proc. Natl. Acad. Sci. USA</u> , 96:1591-1596.	
	C153	Lode et al., (1999), "Tumor-targeted IL-2 Amplifies T Cell-mediated Immune Response Induced by Gene Therapy with Single-chain IL-12," <u>Proc. Natl. Acad. Sci. USA</u> , 96:8591-8596.	
	C154	Lode et al., (2000), "Amplification of T Cell Mediated Immune Responses by Antibody-Cytokine Fusion Proteins," <u>Immunological Investigations</u> , 29(2):117-120.	
	C155	Lode et al., (2000), "What To Do With Targeted IL-2," <u>Drugs of Today</u> , 36(5):321-336.	
	C156	Lode et al., (2000), "Melanoma Immunotherapy by Targeted IL-2 Depends on CD4(+) T-cell Help Mediated by CD40/CD40L Interaction," <u>J. Clin. Invest.</u> , 105(11):1623-30.	
	C157	Macdougall, (2002), "Optimizing the Use of Erythropoietic Agents—Pharmacokinetic and Pharmacodynamic Considerations," <u>Nephrol. Dial. Transplant.</u> , 17(Suppl 5):66-70.	
	C158	Maecker et al., (1997), "DNA Vaccination with Cytokine Fusion Constructs Biases the Immune Response to Ovalbumin," <u>Vaccine</u> , 15(15):1687-1696.	
	C159	Maloney et al., (1994), "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2B8) in Patients with Recurrent B-Cell Lymphoma," <u>Blood</u> , 84(8):2457-2466.	
	C160	Mark et al., (1992), "Expression and Characterization of Hepatocyte Growth Factor Receptor-IgG Fusion Proteins," <u>Journal of Biological Chemistry</u> , 267(36):26166-26171.	
	C161	Martinotti et al., (1995), "CD4 T Cells Inhibit <i>In Vivo</i> the CD8-Mediated Immune Response Against Murine Colon Carcinoma Cells Transduced with Interleukin-12 Genes," <u>Eur. J. Immunol.</u> 25:137-146.	
	C162	Medesan et al., (1997), "Delineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse IgG1," <u>J. Immunology</u> , 158(5):2211-2217.	
	C163	Metelitsa et al., (2002), "Antidisialoganglioside/granulocyte Macrophage-colony-stimulating Factor Fusion Protein Facilitates Neutrophil Antibody-dependent Cellular Cytotoxicity and Depends on Fc $\gamma$ RII (CD32) and Mac-1 (CD11b/CD18) for Enhanced Effector Cell Adhesion and Azurophil Granule Exocytosis," <u>Blood</u> , 99(11):4166-73.	
	C164	Mestre et al., (1997), "Retinoids Suppress Epidermal Growth Factor-induced Transcription of Cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," <u>Cancer Research</u> , 57:2890-2895.	
	C165	Mosmann et al., (1989), "TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties," <u>Ann. Rev. Immunol.</u> , 7:145-173.	
	C166	Mott et al., (1995), "The Solution Structure of the F42A Mutant of Human Interleukin 2," <u>J. Mol. Biol.</u> , 247:979-994.	
	C167	Mueller et al., (1990), "Enhancement of Antibody-Dependent Cytotoxicity With A Chimeric Anti-GD2 Antibody," <u>J. Immunology</u> , 144(4):1382-1386	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>		<b>ATTORNEY DOCKET NO. LEX-023</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b>		<b>APPLICANT(S): Gillies <i>et al.</i></b>	
		<b>SERIAL NO. 10/737,208</b>	<b>CONF. NO. 6855</b>
		<b>FILING DATE: December 16, 2006 GROUP: 1653</b>	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C168	Mueller et al., (1990), "Serum Half-Life and Tumor Localization of a Chimeric Antibody Deleted of the CH2 Domain and Directed Against the Disialoganglioside GD2," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5702-5705.	
	C169	Mueller et al., (1997), "Humanized Porcine VCAM-specific Monoclonal Antibodies with Chimeric IgG2/G4 Constant Regions Block Human Leukocyte Binding to Porcine Endothelial Cells," <u>Molecular Immunology</u> , 34(6):441-452.	
	C170	Mullins et al., (1997), "Taxol-mediated Changes in Fibrosarcoma-induced Immune Cell Function: Modulation of Antitumor Activities," <u>Cancer Immunol. Immunother.</u> , 45:20-28.	
	C171	Mullins et al., (1998), "Interleukin-12 Overcomes Paclitaxel-mediated Suppression of T-cell Proliferation," <u>Immunopharmacol. Immunotoxicol.</u> , 20(4):473-492.	
	C172	Murphy et al., (1986), "Genetic Construction, Expression, and Melanoma-selective Cytotoxicity of a Diphtheria Toxin-related $\alpha$ -melanocyte-stimulating Hormone Fusion Protein," <u>Proc. Natl. Acad. Sci. USA</u> , 83:8258-8262.	
	C173	Murphy, (1988), "Diphtheria-related Peptide Hormone Gene Fusions: A Molecular Gene Approach to Chimeric Toxin Development," in <u>Immunotoxins</u> , pp. 123-140, Frankel (ed.), Kluwer Acad. Pub.	
	C174	Naramura et al., (1993), "Therapeutic Potential of Chimeric and Murine Anti-(Epidermal Growth Factor Receptor) Antibodies in a Metastasis Model for Human Melanoma," <u>Cancer Immuno. Immunother.</u> , 37:343-349.	
	C175	Naramura et al., (1994), "Mechanisms of Cellular Cytotoxicity Mediated by a Recombinant Antibody-IL2 Fusion Protein Against Human Melanoma Cells," <u>Immunology Letters</u> , 39:91-99.	
	C176	Neal et al., (2003), "NXS2 Murine Neuroblastomas Express Increased Levels of MHC Class I Antigens upon Recurrence Following NK-dependent Immunotherapy," <u>Cancer Immunol. Immunother.</u> , 53:41-52.	
	C177	Nedwin et al., (1985), "Human Lymphotoxin and Tumor Necrosis Factor Genes: Structure, Homology and Chromosomal Localization," <u>Nucleic Acids Research</u> , 13(17):6361-6373.	
	C178	Netti et al., (1995), "Time-dependent Behavior of Interstitial Fluid Pressure in Solid Tumors: Implications for Drug Delivery," <u>Cancer Research</u> , 55:5451-5458.	
	C179	Netti et al., (1999), "Enhancement of Fluid Filtration Across Tumor Vessels: Implication for Delivery of Macromolecules," <u>Proc. Nat. Acad. Sci. USA</u> , 96:3137-3142.	
	C180	Neuberger et al., (1984), "Recombinant Antibodies Possessing Novel Effector Functions," <u>Nature</u> , 312:604-608.	
	C181	Ngo et al., (1994), "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz et al. (eds.), pp. 433-440 and 492-495, Birkhauser, Boston, MA.	
	C182	Niethammer et al., (2002) "An Oral DNA Vaccine Against Human Carcinoembryonic Antigen (CEA) Prevents Growth and Dissemination of Lewis Lung Carcinoma in CEA Transgenic Mice," <u>Vaccine</u> , 20:421-429.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



FORM PTO – 1449		ATTORNEY DOCKET NO. LEX-023	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>	
		SERIAL NO. 10/737,208	CONF. NO. 6855
		FILING DATE: December 16, 2006 GROUP: 1653	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C183	Niethammer et al., (2001) "Targeted Interleukin 2 Therapy Enhances Protective Immunity Induced by an Autologous Oral DNA Vaccine against Murine Melanoma," <u>Cancer Research</u> , 61(16):6178-84.	
	C184	Nimtz et al., (1993), "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells," <u>Eur. J. Biochem.</u> , 213:39-56.	
	C185	O'Reilly et al., (1994), "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <u>Cell</u> , 79:315-328.	
	C186	O'Reilly et al., (1996), "Angiostatin Induces and Sustains Dormancy of Human Primary Tumors in Mice," <u>Nature Medicine</u> , 2(6):689-692.	
	C187	O'Reilly et al., (1997), "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <u>Cell</u> , 88:277-285.	
	C188	Pancook et al., (1996), "Eradication of Established Hepatic Human Neuroblastoma Metastases in Mice with Severe Combined Immunodeficiency by Antibody-targeted Interleukin-2," <u>Cancer Immunol. Immunother.</u> , 42(2):88-92.	
	C189	Park et al., (2000), "Efficiency of Promoter and Cell Line in High-level Expression of Erythropoietin," <u>Biotechnol. Appl. Biochem.</u> , 32:167-172.	
	C190	Pastan et al., (1989), " <i>Pseudomonas</i> Exotoxin: Chimeric Toxins," <u>Journal of Biological Chemistry</u> , 264(26):15157-15160.	
	C191	Paul et al., (1988), "Lymphotoxin," <u>Ann. Rev. Immunol.</u> , 6:407-438.	
	C192	Perez et al., (1986), "Specific Targeting of Human Peripheral Blood T Cells by Heteroaggregates Containing Anti-T3 Crosslinked to Anti-Target Cell Antibodies," <u>J. Exp. Med.</u> , 163:166-178.	
	C193	Perez et al., (1989), "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," <u>J. Immunology</u> , 142(10):3662-3667.	
	C194	Pertl et al., (2003), "Immunotherapy with a Posttranscriptionally Modified DNA Vaccine Induces Complete Protection Against Metastatic Neuroblastoma," <u>Blood</u> , 101(2):649-654.	
	C195	Polizzi et al., (1999), "A Novel Taxane with Improved Tolerability and Therapeutic Activity in a Panel of Human Tumor Xenografts," <u>Cancer Research</u> , 59:1036-1040.	
	C196	Putzer et al., (1997), "Interleukin 12 and B7-1 Costimulatory Molecule Expressed by an Adenovirus Vector Act Synergistically to Facilitate Tumor Regression," <u>Proc. Natl. Acad. Sci. USA</u> , 94(20):10889-10894.	
	C197	Reisfeld et al., (1994), "Potential of Genetically Engineered Anti-Ganglioside GD2 Antibodies for Cancer Immunotherapy," <u>Prog. Brain Res.</u> , 101:201-212	
	C198	Reisfeld et al., (1996), "Antibody-interleukin 2 Fusion Proteins: A New Approach to Cancer Therapy," <u>J. Clin. Lab. Anal.</u> , 10:160-166.	
EXAMINER		DATE CONSIDERED	

<b>FORM PTO – 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTORNEY DOCKET NO. LEX-023  APPLICANT(S): Gillies <i>et al.</i>  SERIAL NO. 10/737,208                      CONF. NO. 6855  FILING DATE: December 16, 2006    GROUP: 1653	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C199	Reisfeld et al., (1996), "Involvement of B Lymphocytes in the Growth Inhibition of Human Pulmonary Melanoma Metastases in Athymic <i>nu/nu</i> Mice by an Antibody-lymphotoxin Fusion Protein," <u>Cancer Research</u> , 56(8):1707-1712.	
	C200	Reisfeld et al., (1996), "Recombinant Antibody Fusion Proteins for Cancer Immunotherapy," <u>Current Topics in Microbiology and Immunology</u> , 213:27-53.	
	C201	Reisfeld et al., (1997), "Immunocytokines: A New Approach to Immunotherapy of Melanoma," <u>Melanoma Research</u> , 7(Supp2):S99-S106.	
	C202	Riethmuller et al., (1994), "Randomised Trial of Monoclonal Antibody for Adjuvant Therapy of Resected Dukes' C Colorectal Carcinoma," <u>The Lancet</u> , 343:1177-1183.	
	C203	Roessler et al., (1994), "Cooperative Interactions Between the Interleukin 2 Receptor $\alpha$ and $\beta$ Chains Alter the Interleukin 2-binding Affinity of the Receptor Subunits," <u>Proc. Natl. Acad. Sci. USA</u> , 91:3344-3347.	
	C204	Roitt et al., (1993), "The Role of TH Cells in the Selection of Effector Mechanisms Directed Against Target Antigens," <u>Immunology</u> , 3 <sup>rd</sup> Ed., pp. 8.3-8.4.	
	C205	Rosenberg, (1988), "Immunotherapy of Cancer Using Interleukin 2: Current Status and Future Prospects," <u>Immunology Today</u> , 9(2):58-62.	
	C206	Rozwarski et al., (1994), "Structural Comparisons Among the Short-chain Helical Cytokines," <u>Structure</u> , 2(3):159-173.	
	C207	Ruehlmann et al., (2001), "MIG (CIXCL9) Chemokine Gene Therapy Combines with Antibody-cytokine Fusion Protein to Suppress Growth and Dissemination of Murine Colon Carcinoma," <u>Cancer Research</u> , 61(23):8498-503.	
	C208	Sabzevari et al., (1994), "A Recombinant Antibody-interleukin 2 Fusion Protein Suppresses Growth of Hepatic Human Severe Combined Immunodeficiency Mice," <u>Proc. Natl. Acad. Sci. USA</u> , 91(20):9626-30.	
	C209	Saleh et al., (1992), "Phase I Trial of the Chimeric Anti-GD2 Monoclonal Antibody ch14.18 in Patients With Malignant Melanoma," <u>Hum. Antib. Hybridomas</u> , 3:19-24.	
	C210	Sallusto et al., (1994), "Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor $\alpha$ ," <u>J. Exp. Med.</u> , 179:1109-1118.	
	C211	Santon et al., (1986), "Effects of Epidermal Growth Factor Receptor Concentration on Tumorigenicity of A431 Cells in Nude Mice," <u>Cancer Research</u> , 46:4701-4705.	
	C212	Sasaki et al., (1998), "Structure, Function and Tissue Forms of the C-terminal Globular Domain of Collagen XVIII Containing the Angiogenesis Inhibitor Endostatin," <u>EMBO Journal</u> , 17(15):4249-4256.	
	C213	Sauve et al., (1991), "Localization in Human Interleukin 2 of the Binding Site to the $\alpha$ -chain (p55) of the Interleukin 2 Receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 88:4636-4640.	
	C214	Schlom (1991), "Monoclonal Antibodies: They're More and Less Than You Think," in <u>Molecular Foundations of Oncology</u> , pp. 95-133.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTORNEY DOCKET NO. LEX-023  APPLICANT(S): Gillies <i>et al.</i>  SERIAL NO. 10/737,208                      CONF. NO. 6855  FILING DATE: December 16, 2006    GROUP: 1653	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C215	Schnee et al., (1987), "Construction and Expression of a Recombinant Antibody-targeted Plasminogen Activator," <u>Proc. Natl. Acad. Sci. USA</u> , 84:6904-6908.	
	C216	Schoenhaut et al., (1992), "Cloning and Expression of Murine IL-12," <u>J. Immunology</u> , 148(11):3433-3340.	
	C217	Seidenfeld et al., (2001), "Epoietin Treatment of Anemia Associated with Cancer Therapy: A Systematic Review and Meta-analysis of Controlled Clinical Trials," <u>Journal of National Cancer Institute</u> , 93(16):1204-1214.	
	C218	Senter et al., (1988), "Anti-tumor Effects of Antibody-alkaline Phosphatase Conjugates in Combination with Etoposide Phosphate," <u>Proc. Natl. Acad. Sci. USA</u> , 85(13):4842-4846.	
	C219	Shanafelt et al., (2000), "A T-cell-Selective Interleukin 2 Mutein Exhibits Potent Antitumor Activity and is Well Tolerated <i>In Vivo</i> ," <u>Nature Biotechnology</u> , 18:1197-1202.	
	C220	Sharma et al., (1999), "T cell-derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T cell and APC Function," <u>Journal of Immunology</u> , 163:5020-5028.	
	C221	Shen et al., (1986), "Heteroantibody-Mediated Cytotoxicity: Antibody to the High Affinity Fc Receptor for IgG Mediates Cytotoxicity by Human Monocytes That is Enhanced by Interferon- $\gamma$ and is Not Blocked by Human IgG," <u>J. Immunology</u> , 137(11):3378-3382.	
	C222	Shiff et al., (1995), "Sulindac Sulfide, an Aspirin-like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells," <u>Journal of Clinical Investigation</u> , 96:491-503.	
	C223	Shin et al., (1990), "Expression and Characterization of an Antibody Binding Specificity Joined to Insulin-like Growth Factor 1: Potential Applications for Cellular Targeting," <u>Proc. Natl. Acad. Sci. USA</u> , 87:5322-5326.	
	C224	Shinkawa et al., (2003), "The Absence of Fucose But Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," <u>J. Biol. Chem.</u> , 278:3466-3473.	
	C225	Sim et al., (1997), "A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer," <u>Cancer Research</u> , 57:1329-1334.	
	C226	Spiekermann et al., (2002), "Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life: Functional Expression of FcRn in the Mammalian Lung," <u>J. Exp. Med.</u> , 196:303-310.	
	C227	Stevenson et al., (1997), "Conjugation of Human Fc $\gamma$ in Closed-Hinge or Open-Hinge Configuration to Fab' $\gamma$ and Analogous Ligands," <u>J. Immunology</u> , 158:2242-2250.	
	C228	Strom et al., (1996), "Therapeutic Approach to Organ Transplantation," Chapter 36, pp. 451-456, in <u>Therapeutic Immunology</u> , Austen et al., (eds.), Blackwell Science.	
	C229	Sulitzeanu, (1993), "Immunosuppressive Factors in Human Cancer," pp. 247-266 in <u>Advances in Cancer Research</u> , Vol. 60, Vande Woude et al. (eds.), Academic Press, Inc.	
	C230	Syed et al., (1998), "Efficiency of Signaling Through Cytokine Receptors Depends Critically on Receptor Orientation," <u>Nature</u> , 395:511-516.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>FORM PTO – 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>		ATTORNEY DOCKET NO. LEX-023  APPLICANT(S): Gillies <i>et al.</i>  SERIAL NO. 10/737,208                      CONF. NO. 6855  FILING DATE: December 16, 2006    GROUP: 1653	
<b>EXAM. INIT.</b>	<b>OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)</b>		
	C231	Taniguchi et al., (1983), "Structure and Expression of a Cloned cDNA for Human Interleukin-2," <u>Nature</u> , 302:305-309.	
	C232	Tao et al., (1989), "Studies of Aglycosylated Chimeric Mouse IgG: Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," <u>J. Immunology</u> , 143(8):2595-2601.	
	C233	Tao et al., (1993), "Structural Features of Human Immunoglobulin G that Determine Isotype-Differences in Complement Activation," <u>J. Exp. Med.</u> , 178(2):661-667.	
	C234	Teicher et al., (1994), "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents," <u>Int. J. Cancer</u> , 57:920-925.	
	C235	<u>The Merck Manual of Diagnosis and Therapy</u> , 17 <sup>th</sup> Ed., (1999) pp. 990-993 and 1278-1283.	
	C236	Thommesen et al., (2000), "Lysine 322 in the Human IgG3 CH2 Domain is Crucial for Antibody Dependent Complement Activation," <u>Mol. Immunol.</u> , 37(16):995-1004.	
	C237	Till et al., (1988), "An Assay that Predicts the Ability of Monoclonal Antibodies to Form Potent Ricin A Chain-containing Immunotoxins," <u>Cancer Research</u> , 48(5):1119-1123	
	C238	Till et al., (1988), "HIV-Infected Cells are Killed by rCD4-Ricin A Chain," <u>Science</u> , 242:1166-1168	
	C239	Trinchieri, (1994), "Interleukin-12: A Cytokine Produced by Antigen-Presenting Cells With Immunoregulatory Functions in the Generation of T-Helper Cells Type 1 and Cytotoxic Lymphocytes," <u>Blood</u> , 84:4008-4027.	
	C240	Vagliani et al., (1996), "Interleukin 12 Potentiates the Curative Effect of a Vaccine Based on Interleukin 2-transduced Tumor Cells," <u>Cancer Research</u> , 56:467-470.	
	C241	Varki et al., (1984), "Antigens Associated with a Human Lung Adenocarcinoma Defined by Monoclonal Antibodies," <u>Cancer Research</u> , 44:681-687.	
	C242	Verhoeyen et al., (1988), "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," <u>Science</u> , 239:1534-1536.	
	C243	Villunger et al., (1997), "Constitutive Expression of Fas (Apo-1/CD95) Ligand on Multiple Myeloma Cells: A Potential Mechanism of Tumor-induced Suppression of Immune Surveillance," <u>Blood</u> , 90(1):12-20.	
	C244	Watanabe et al., (1997), "Long-term Depletion of Naive T cells in Patients Treated for Hodgkin's Disease," <u>Blood</u> , 90(9):3662-3672.	
	C245	Weber et al., (2001), "Phase I Trial of huKS-IL2 Immunocytokine in Patients with Prostate Carcinoma: Clinical, PK, and Biological PD Results (Abstract)," <u>American Society of Clinical Oncology Program/Proceedings</u> , 20(Part 1):259a.	
	C246	Wells, (1990), "Additivity of Mutational Effect in Proteins," <u>Biochemistry</u> , 29(37):8509-8517.	
	C247	Wen et al., (1993), "Erythropoietin Structure-Function Relationships: High Degree of Sequence Homology Among Mammals," <u>Blood</u> , 82(5):1507-1516.	
	C248	Wen et al., (1994), "Erythropoietin Structure-Function Relationships: Identification of Functionally Important Domains," <u>J. Biological Chemistry</u> , 269(36):22839-22846.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

FORM PTO – 1449		ATTORNEY DOCKET NO. LEX-023	
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Gillies <i>et al.</i>	
		SERIAL NO. 10/737,208	CONF. NO. 6855
		FILING DATE: December 16, 2006 GROUP: 1653	
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)		
	C249	Williams et al., (1986), "Production of Antibody-tagged Enzymes by Myeloma Cells: Application to DNA Polymerase I Klenow Fragment," <u>Gene</u> , 43:319-324.	
	C250	Williams et al., (1987), "Diphtheria Toxin Receptor Binding Domain Substitution with Interleukin-2: Genetic Construction and Properties of a Diphtheria Toxin-related Interleukin-2 Fusion Protein," <u>Protein Engineering</u> , 1(6):493-498.	
	C251	Wooley et al., (1993), "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor Fc Fusion Protein on Type II Collagen-Induced Arthritis in Mice," <u>J. Immunology</u> , 151:6602-6607.	
	C252	Wu et al., (1997), "Suppression of Tumor Growth with Recombinant Murine Angiostatin," <u>Biochemical and Biophysical Research Communications</u> , 236:651-654.	
	C253	Xiang et al., (1997), "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," <u>Cancer Research</u> , 57:4948-4955.	
	C254	Xiang et al., (1998), "Induction of Persistent Tumor-protective Immunity in Mice Cured of Established Colon Carcinoma Metastases," <u>Cancer Research</u> , 58(17):3918-3925.	
	C255	Xiang et al., (1999) "T Cell Memory against Colon Carcinoma is Long-lived in the Absence of Antigen," <u>J. Immunology</u> , 163(7):3676-83.	
	C256	Xiang et al., (2001), "A Dual Function DNA Vaccine Encoding Carcinoembryonic Antigen and CD40 Ligand Trimer Induces T Cell-mediated Protective Immunity Against Colon Cancer in Carcinoembryonic Antigen-Transgenic Mice," <u>J. Immunology</u> , 167(8):4560-5.	
	C257	Xiang et al., (2001), "Protective Immunity Against Human Carcinoembryonic Antigen (CEA) Induced by an Oral DNA Vaccine in CEA-transgenic Mice," <u>Clinical Cancer Research</u> , 7(3 Supp):S856-S864.	
	C258	Xu et al., (1994), "Residue at Position 331 in the IgG1 and IgG4 CH2 Domains Contributes to Their Differential Ability to Bind and Activate Complement," <u>J. Biol. Chem.</u> , 269(5):3469-3474.	
	C259	Yu et al., (1998), "Phase I Trial of a Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 in Patients with Refractory Neuroblastoma and Osteosarcoma," <u>J. Clinical Oncology</u> , 16(6):2169-80.	
	C260	Zagozdzon et al., (1999), "Potentiation of Antitumor Effects of IL-12 in Combination with Paclitaxel in Murine Melanoma Model <i>In Vivo</i> ," <u>International Journal of Molecular Medicine</u> , 4:645-648.	
	C261	Zheng et al., (1995), "Administration of Noncytolytic IL-10/Fc in Murine Models of Lipopolysaccharide-induced Septic Shock and Allogenic Islet Transplantation," <u>J. Immunology</u> , 154:5590-5600.	
EXAMINER		DATE CONSIDERED	

3061087